Urothelial CarcinomaOUAFNCT07334314
Olfactive Detection of Urothelial Carcinoma by Sniffer Dogs
An observational study of Urothelial Carcinoma, run by University Hospital, Strasbourg, France at 2 sites in France.
Trial summary
The aim of this study is to estimate the sensitivity of olfactory detection of urothelial carcinomas of the bladder in urine samples by assistance dogs trained in this practice. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Urothelial Carcinoma
- What is being tested?
- olfactory detection by dogs
- How many people
- 340 participants
- Where
- 2 sitesFrance
- Study dates
- 20 Jun 2025to Sep 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Subject scheduled for any endourological surgery involving an initial cystoscopy, the most common of which are: transurethral resection of the bladder, transurethral resection of the prostate, internal optical urethrotomy, bladder lithoclast, ureteral stent replacement, ureteroscopy, etc. (non-exhaustive list). Recruitment will take place in the urology department, during the preoperative consultation or during hospitalization.
Who may be able to join
- Adult (> 18 years old)
- Subject scheduled for any endourological surgery involving an initial cystoscopy, the most common of which are: transurethral resection of the bladder, transurethral resection of the prostate, internal optical urethrotomy, bladder lithoclast, ureteral stent replacement, ureteroscopy, etc. (non-exhaustive list)
- Subjects for whom a urine sample (for bacteriological or cytological testing) is planned as part of routine practice in the month prior to the procedure
- Subjects affiliated with a health insurance plan or beneficiaries of such a plan
Who cannot join
- Absence of signed informed consent / inability to provide the subject with informed information (emergency situations, difficulties in understanding the subject, etc.)
- Patient under guardianship, conservatorship, or judicial protection
- History of cancer other than urothelial bladder carcinoma, unless in complete remission for > 5 years
- Pregnant or breastfeeding women
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
France2 sites, 2 recruiting
- Recruiting
Hôpitaux Civils de Colmar
Colmar
Marc SCHNEIDER, +33 3 89 12 49 93, schneidermarc1@gmail.com
schneidermarc1@gmail.com
- Recruiting
Hôpitaux Universitaires de Strasbourg
Strasbourg
Victor GAILLARD, +33 3 69 55 10 55, victor.gaillard@chru-strasbourg.fr
Victor GAILLARD
About this study
The aim of this study is to estimate the sensitivity of olfactory detection of urothelial carcinomas of the bladder in urine samples by assistance dogs trained in this practice.
- Conditions
- Urothelial Carcinoma
- Being tested
- olfactory detection by dogs
- Medical subject headings
- Carcinoma, Transitional Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
olfactory detection by dogsDiagnostic test
olfactory detection of urothelial carcinoma of the bladder in a urine sample by dogs
| Study group | Role | What they receive |
|---|---|---|
| Positive bladder tumor | Bladder tumor present during cystoscopy and confirmed by pathological examination. Receives: Diagnostic Test: olfactory detection by dogs | |
| Negative bladder tumor | No bladder tumor on cystoscopy/suspicious lesion but with negative pathological analysis Receives: Diagnostic Test: olfactory detection by dogs |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assess the sensitivity of olfactory detection of urothelial carcinomas of the bladder in urine samples by assistance dogs trained for this purpose
Measured: Day -60 to Day 0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2026
- Study start20 Jun 2025
- Primary completionSep 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Urothelial CarcinomaStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 340 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07334314
- Sponsor's protocol ID
- 9630
- Acronym
- OUAF
- Status last verified
- Dec 2025
- First submitted
- 10 Dec 2025
- Last updated
- 12 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Olfactive Detection of Urothelial Carcinoma by Sniffer Dogs
- ClinicalTrials.gov ID
- NCT07334314
- Acronym / sponsor ID
- OUAF / 9630
- Conditions
- Urothelial Carcinoma
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 340 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 20 Jun 2025 (actual)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Sep 2026 (estimated)
- First posted
- 12 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to estimate the sensitivity of olfactory detection of urothelial carcinomas of the bladder in urine samples by assistance dogs trained in this practice.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Positive bladder tumor | – | Diagnostic Test: olfactory detection by dogsBladder tumor present during cystoscopy and confirmed by pathological examination. |
| Negative bladder tumor | – | Diagnostic Test: olfactory detection by dogsNo bladder tumor on cystoscopy/suspicious lesion but with negative pathological analysis |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Subject scheduled for any endourological surgery involving an initial cystoscopy, the most common of which are: transurethral resection of the bladder, transurethral resection of the prostate, internal optical urethrotomy, bladder lithoclast, ureteral stent replacement, ureteroscopy, etc. (non-exhaustive list). Recruitment will take place in the urology department, during the preoperative consultation or during hospitalization.
Key inclusion criteria (4 listed)
- Adult (> 18 years old)
- Subject scheduled for any endourological surgery involving an initial cystoscopy, the most common of which are: transurethral resection of the bladder, transurethral resection of the prostate, internal optical urethrotomy, bladder lithoclast, ureteral stent replacement, ureteroscopy, etc. (non-exhaustive list)
- Subjects for whom a urine sample (for bacteriological or cytological testing) is planned as part of routine practice in the month prior to the procedure
- Subjects affiliated with a health insurance plan or beneficiaries of such a plan
Key exclusion criteria (4 listed)
- Absence of signed informed consent / inability to provide the subject with informed information (emergency situations, difficulties in understanding the subject, etc.)
- Patient under guardianship, conservatorship, or judicial protection
- History of cancer other than urothelial bladder carcinoma, unless in complete remission for > 5 years
- Pregnant or breastfeeding women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| olfactory detection by dogsolfactory detection of urothelial carcinoma of the bladder in a urine sample by dogs | Diagnostic test | Negative bladder tumor, Positive bladder tumor |
Primary outcome
Assess the sensitivity of olfactory detection of urothelial carcinomas of the bladder in urine samples by assistance dogs trained for this purpose
Time frame: Day -60 to Day 0
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2026.
Related trials for Urothelial Carcinoma
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingObservational study
Registry Platform Urologic Cancer
Renal Cell Carcinoma, Urothelial Carcinoma
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Urothelial Carcinoma, run by University Hospital, Strasbourg, France at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Victor GAILLARD (+33 3 69 55 10 55, victor.gaillard@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assess the sensitivity of olfactory detection of urothelial carcinomas of the bladder in urine samples by assistance dogs trained for this purpose (time frame: Day -60 to Day 0). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2026.